Type 2 Diabetes

Associated Outcomes for Metformin-Based Diabetes Treatment After Kidney Transplant

Associated Outcomes for Metformin-Based Diabetes Treatment After Kidney Transplant

By

Outcomes associated with metformin use for diabetes in patients requiring kidney transplantation were assessed in an observational study linking Scientific Registry of Transplant Recipient data with US pharmacy claims data.

Increased Risk for Parkinson Disease in Individuals With Type 2 Diabetes

Increased Risk for Parkinson Disease in Individuals With Type 2 Diabetes

By

A retrospective cohort study was conducted to determine whether individuals with preexisting type 2 diabetes are at increased risk of developing Parkinson disease.

Information-Motivation-Behavioral Skills Model Identifies Barriers to Diabetes Medication Adherence

Information-Motivation-Behavioral Skills Model Identifies Barriers to Diabetes Medication Adherence

By

Investigators used the Information-Motivation-Behavioral skills model of adherence to examine associations between patient characteristics and barriers to adherence to treatment for type 2 diabetes.

Dulaglutide Assessed in T2D Patients With Chronic Kidney Disease

Dulaglutide Assessed in T2D Patients With Chronic Kidney Disease

By

In AWARD-7, eligible patients (N=577) were randomized to receive dulaglutide 1.5mg once-weekly (N=193), dulaglutide 0.75mg (N=190) once-weekly, or insulin glargine daily (N=194), all in combination with insulin lispro, for 52 weeks. HbA1c at 26 weeks with a 0.4% non-inferiority margin was designated as the primary outcome, while secondary outcomes included eGFR and urine albumin-to-creatinine ratio.

Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes

Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes

Investigators examined the safety and efficacy of empagliflozin 10mg and linagliptin 5 mg in patients uncontrolled on linagliptin.

LV Strain, Hypertrophy Predict Heart Failure in Asymptomatic T2D

LV Strain, Hypertrophy Predict Heart Failure in Asymptomatic T2D

By

Impaired global longitudinal strain and left ventricular hypertrophy may be predictive of incident heart failure in patients with asymptomatic type 2 diabetes.

SGLT2 Inhibitor Use Linked to Lower Risk for Heart Failure, Death in Type 2 Diabetes

SGLT2 Inhibitor Use Linked to Lower Risk for Heart Failure, Death in Type 2 Diabetes

By

Regardless of presence of preexisting cardiovascular disease, SGLT2 inhibitors were associated with lower risk for death and heart failure.

Fenofibrate Improves Cholesterol Levels in Type 2 Diabetes

Fenofibrate Improves Cholesterol Levels in Type 2 Diabetes

By

To understand the mechanism underlying the benefit of fenofibrate on vascular complications in patients with type 2 diabetes, investigators assessed carotid intima thickness as a marker of subclinical atherosclerosis.

Does Metformin Use Increase the Risk for Lactic Acidosis in T2D Patients?

Does Metformin Use Increase the Risk for Lactic Acidosis in T2D Patients?

Results demonstrated an incidence rate of 391/100,000 person years was calculated based on the 163 patients who were hospitalized with lactic acidosis during the follow-up period.

Diabetes Exposure in Utero and Risk of Developing T2D in Offspring

Diabetes Exposure in Utero and Risk of Developing T2D in Offspring

By

This study demonstrated the importance of early screening and diagnosis of type 2 diabetes in mothers and their offspring.

Safety of DPP-IV Inhibitor, Cardiovascular Events After ACS in Type 2 Diabetes

Safety of DPP-IV Inhibitor, Cardiovascular Events After ACS in Type 2 Diabetes

By

Investigators examined the time to first event composing of cardiovascular death, myocardial infarction, or stroke.

Predictors of Success for Insulin-to-Liraglutide Switch for Type 2 Diabetes

Predictors of Success for Insulin-to-Liraglutide Switch for Type 2 Diabetes

By

Investigators examined predictors of success of switching from insulin to liraglutide in patients with type 2 diabetes.

Abnormal Glucose Regulation Associated With Cognitive Dysfunction in HIV+ Men

Abnormal Glucose Regulation Associated With Cognitive Dysfunction in HIV+ Men

By

A study sought to determine the relationship between glycemic status and cognition in people living with HIV.

MK-1293 Insulin Glargine is a Safe and Effective Treatment Option for Type 2 Diabetes

MK-1293 Insulin Glargine is a Safe and Effective Treatment Option for Type 2 Diabetes

By

Investigators sought to determine the safety and efficacy of MK-1293 insulin glargine and Lantus in type 2 diabetes.

Contribution of Low-Severity Gestational Diabetes Mellitus on the Diabetes Epidemic

Contribution of Low-Severity Gestational Diabetes Mellitus on the Diabetes Epidemic

By

Greater awareness of clinical and cost implications of gaps for patients with lower-severity gestational diabetes may improve postdelivery testing and referral.

Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI

Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI

By

Researchers assessed whether semaglutide-induced weight loss was related to gastrointestinal adverse events.

Composite HbA1c End Point Can Better Gauge Response to Basal Insulin in Type 2 Diabetes

Composite HbA1c End Point Can Better Gauge Response to Basal Insulin in Type 2 Diabetes

By

Investigators sought to determine baseline and clinical characteristics associated with response to insulin glargine in patients with type 2 diabetes.

Effect of Testosterone Replacement on Glycemic Control in Obese Men With Hypogonadism, T2D

Effect of Testosterone Replacement on Glycemic Control in Obese Men With Hypogonadism, T2D

By

Investigators examined the effect of testosterone replacement therapy on metabolic syndrome and vascular function in obese males with hypogonadism.

Oral Semaglutide Tops Empagliflozin for HbA1c Improvement: PIONEER 2 Trial

Oral Semaglutide Tops Empagliflozin for HbA1c Improvement: PIONEER 2 Trial

By

Oral semaglutide 14 mg led to statistically significant improvement in hemoglobin A1c levels and weight loss in adults with type 2 diabetes.

Fewer Major Adverse Cardiovascular Events With New Antihyperglycemic Drugs With Lower Hypoglycemic Risk

Fewer Major Adverse Cardiovascular Events With New Antihyperglycemic Drugs With Lower Hypoglycemic Risk

By

Investigators proposed that reduction in MACE may be proportional to the magnitude of HbA1c reduction seen with newer antihyperglycemic agents.

Heart Rate Variability in Type 2 Diabetes

Heart Rate Variability in Type 2 Diabetes

By

Researchers conducted a systemic review and met-analysis to examine the effect of type 2 diabetes on heart rate variability.

Ideal Systolic Blood Pressure for CVD Prevention in Diabetes, Hypertension

Ideal Systolic Blood Pressure for CVD Prevention in Diabetes, Hypertension

By

Investigators sought to determine whether targeting systolic blood pressure of 140 mmHg in patients with type 2 diabetes would result in adverse CV outcomes.

Increased Risk for Type 2 Diabetes in Adolescents, Young Adults With ADHD

Increased Risk for Type 2 Diabetes in Adolescents, Young Adults With ADHD

These findings can inform clinical practice in that type 2 diabetes should be considered in ADHD even in the absence of other known risk factors.

Perioperative Cardiovascular Events More Common in Diabetes

Perioperative Cardiovascular Events More Common in Diabetes

By

Perioperative major adverse cardiovascular and cerebrovascular events may be more common in patients with diabetes.

Childhood Overweight Increases Risk for Type 2 Diabetes in Adulthood

Childhood Overweight Increases Risk for Type 2 Diabetes in Adulthood

By

Investigators examined changes in weight from childhood to early adulthood and the risk for developing type 2 diabetes.

Diabetes, HbA1c Independently Associated With Adverse Postoperative Outcomes

Diabetes, HbA1c Independently Associated With Adverse Postoperative Outcomes

By

Investigators sought to determine an association between diabetes and HbA1C with postoperative outcomes.

Semaglutide Superior to Other GLP-1 Analogues as Add-On to Basal Insulin in T2D

Semaglutide Superior to Other GLP-1 Analogues as Add-On to Basal Insulin in T2D

By

Overall, once-weekly semaglutide 1.0 mg as an add-on to basal insulin is the most efficacious GLP-1 receptor agonist in terms of reductions in HbA1c and body weight from baseline after 6 months of treatment.

Clinician Perspective: Examining the Link Between Antipsychotics and Diabetes

Clinician Perspective: Examining the Link Between Antipsychotics and Diabetes

By

Endocrinologist Kevin M. Pantalone, DO, and psychiatrist Christian Kohler, MD, discuss the risk associated with the use of antipsychotic medications in individuals with type 2 diabetes.

ADA Issues White Paper Addressing Escalating Cost of Insulin

ADA Issues White Paper Addressing Escalating Cost of Insulin

By

There is a lack of transparency throughout the insulin supply chain. It is unclear precisely how the dollars flow and how much each intermediary profits.

Triple-Goal Achievement Reduces Risk for Complications in Type 2 Diabetes

Triple-Goal Achievement Reduces Risk for Complications in Type 2 Diabetes

By

Treatment strategies targeting hypertension, hyperlipidemia, and hyperglycemia may improve outcomes in patients with type 2 diabetes.

Sign Up for Free e-Newsletters



CME Focus